fingolimod hydrochloride has been researched along with transforming growth factor beta in 19 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatori, M; Ichimaru, N; Morozumi, K; Okuyama, A; Suzuki, K; Suzuki, S; Takahara, S; Tanaka, T; Wang, J; Yamanaka, H | 1 |
| Itoh, M; Kataoka, H; Kuno, A; Nakao, H; Ogawa, K; Ohara, H; Okamoto, T; Sano, H; Shirai, T; Tang, M; Yamada, T | 1 |
| Eberhardt, W; Huwiler, A; Pfeilschifter, J; Ren, S; Xin, C | 1 |
| Ahn, KO; Bang, BK; Choi, BS; Kim, J; Kim, JS; Kim, JY; Kim, YS; Li, C; Lim, SW; Yang, CW; Yang, HJ | 1 |
| Chun, J; Keller, CD; Kleuser, B; Radeke, HH; Rivera Gil, P; Schäfer-Korting, M; Tölle, M; van der Giet, M | 1 |
| Budde, K; Daig, U; Krämer, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Wang-Rosenke, Y | 1 |
| Rouse, BT; Sehrawat, S | 1 |
| Binder, E; Budde, K; Khadzhynov, D; Krämer, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Wang-Rosenke, Y | 1 |
| Gong, Y; Huang, Y; Jiang, J; Li, Y; Liu, Y; Wang, X; Xiao, H | 1 |
| Brane, L; Cheong, C; Choi, JH; Do, Y; Lavelle, EC; Mayer, L; Mehandru, S; Mucida, D; Poles, J; Reis, BS; Ruane, D; Steinman, RM; Studt, N; Velinzon, K; Zhu, H | 1 |
| Ching, D; Eberlé, D; Honbo, N; Imhof, I; Karliner, JS; Kim, RY; Kumar, N; Li, K; Luk, FS; Raffai, RL; Wang, G; Zhu, BQ | 1 |
| Lv, L; Qian, J; Ye, S; Ye, Y; Zhu, C | 1 |
| Hu, S; Jin, Y; Ni, H; Xu, H; Zhang, Q | 1 |
| Blumenfeld, S; Miller, A; Staun-Ram, E | 1 |
| Agostini, S; Caputo, D; Clerici, M; La Rosa, F; Longhi, R; Marventano, I; Mendozzi, L; Piancone, F; Rovaris, M; Saresella, M; Zoppis, M | 1 |
| Huang, Z; Kumar T, P; Ma, S; Santhosh, D | 1 |
| Shi, D; Tian, T; Wen, S; Zhang, J; Zhou, H; Zhu, X | 1 |
| Anders, RA; Carrera-Haro, MA; Drake, CG; Ghasemzadeh, A; Kochel, CM; Lopez-Bujanda, Z; Mao, W; Marciscano, AE; Meeker, AK; Muroyama, Y; Nirschl, TR; Pardoll, DM; Tam, AJ; Theodros, D; Thoburn, CJ; Uddin, M; Velarde, E | 1 |
| Blumenfeld-Kan, S; Miller, A; Staun-Ram, E | 1 |
19 other study(ies) available for fingolimod hydrochloride and transforming growth factor beta
| Article | Year |
|---|---|
A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine.
Topics: Apoptosis; Cell Movement; Cyclosporine; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine; Transforming Growth Factor beta; Tumor Cells, Cultured | 2002 |
FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration.
Topics: Animals; Body Weight; Fingolimod Hydrochloride; Hydroxyproline; Immunosuppressive Agents; Interferon-gamma; Male; Organ Size; Pancreas; Pancreatitis, Chronic; Peroxidase; Propylene Glycols; Rats; Rats, Wistar; RNA, Messenger; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.
Topics: Animals; Cells, Cultured; Collagen Type IV; Connective Tissue Growth Factor; Fibrosis; Fingolimod Hydrochloride; Glomerular Mesangium; Immediate-Early Proteins; Immunosuppressive Agents; Intercellular Signaling Peptides and Proteins; Male; MAP Kinase Signaling System; Phosphorylation; Propylene Glycols; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Smad1 Protein; Smad2 Protein; Smad3 Protein; Sphingosine; Transforming Growth Factor beta; Up-Regulation | 2006 |
Effect of FTY720 on chronic cyclosporine nephropathy in rats.
Topics: Angiotensin II; Animals; Chronic Disease; Cyclosporine; Extracellular Matrix Proteins; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Osteopontin; Propylene Glycols; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.
Topics: Animals; Cell Differentiation; Cells, Cultured; Extracellular Matrix Proteins; Fibroblasts; Fingolimod Hydrochloride; Immunologic Factors; Mice; Mice, Knockout; Muscle, Smooth; Phosphorylation; Propylene Glycols; Receptor Cross-Talk; Receptors, Lysosphingolipid; Signal Transduction; Smad3 Protein; Sphingosine; Transforming Growth Factor beta | 2007 |
S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Topics: Animals; Antibodies, Blocking; Blood Pressure; Body Weight; Collagen Type III; Extracellular Matrix; Fibronectins; Fingolimod Hydrochloride; Glomerulonephritis, Membranoproliferative; Heart Rate; Immunohistochemistry; Kidney Glomerulus; Leukocyte Count; Lipopolysaccharides; Male; Nitric Oxide Synthase Type II; Plasminogen Activator Inhibitor 1; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thy-1 Antigens; Transforming Growth Factor beta | 2007 |
Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators.
Topics: Animals; CD4-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Forkhead Transcription Factors; Herpesvirus 1, Human; Immunosuppressive Agents; Keratitis, Herpetic; Lymphocyte Count; Mice; Mice, Mutant Strains; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2008 |
The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
Topics: Animals; Blood Pressure; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Matrix; Fibrosis; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Nephrectomy; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Sphingosine; Transforming Growth Factor beta | 2009 |
The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro.
Topics: Animals; Cell Proliferation; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immunosuppressive Agents; Interleukin-10; Male; Mice; Mice, Inbred BALB C; Organophosphates; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2012 |
Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract.
Topics: Administration, Intranasal; Adoptive Transfer; Animals; Antigens, CD; Antigens, Surface; Basic-Leucine Zipper Transcription Factors; Cell Movement; Dendritic Cells; Fingolimod Hydrochloride; Gastrointestinal Tract; Immunity, Mucosal; Immunization; Integrins; Intestinal Mucosa; Lectins, C-Type; Lung; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, CCR; Salmonella; Salmonella Infections, Animal; Signal Transduction; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Tretinoin | 2013 |
The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction.
Topics: Animals; Apolipoproteins E; Cardiotonic Agents; Coronary Artery Disease; Diet, High-Fat; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Propylene Glycols; Sphingosine; Survival Rate; T-Lymphocytes, Regulatory; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left | 2014 |
FTY720 attenuates paraquat-induced lung injury in mice.
Topics: Actins; Acute Lung Injury; Animals; Body Weight; Bronchoalveolar Lavage Fluid; Collagen Type I; Collagen Type III; Disease Models, Animal; Fingolimod Hydrochloride; Interleukin-1beta; Interleukin-6; Lung; Lung Injury; Mice; Mice, Inbred C57BL; Paraquat; Propylene Glycols; Pulmonary Edema; Pulmonary Fibrosis; Sphingosine; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2014 |
Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats.
Topics: Ammonia; Animals; Blood Glucose; Capillaries; Cell Adhesion Molecules; Collagen; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Gene Expression Regulation; Interleukin-6; Lysophospholipids; Male; Microcirculation; Myocardium; Nitrogen Radioisotopes; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Transforming Growth Factor beta | 2014 |
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Topics: Adult; Antigen Presentation; B-Lymphocyte Subsets; Cell Differentiation; Cell Survival; Cytokines; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Immunologic Memory; Immunophenotyping; Immunosuppressive Agents; Inflammation Mediators; Interleukin-10; Leukocyte Count; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Plasma Cells; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Transforming Growth Factor beta; Young Adult | 2016 |
B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.
Topics: Adult; Antigens, CD19; B-Lymphocytes, Regulatory; Cells, Cultured; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Multiple Sclerosis; Receptors, Immunologic; Severity of Illness Index; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
A Brain-Region-Specific Neural Pathway Regulating Germinal Matrix Angiogenesis.
Topics: Brain; Embryo, Mammalian; Enzyme Activation; Fingolimod Hydrochloride; Guanine Nucleotide Exchange Factors; Hemorrhage; Humans; Integrin beta Chains; Lysophospholipids; Mutation; Neostriatum; Neovascularization, Physiologic; Neural Pathways; Neural Stem Cells; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Phenotype; Receptors, Lysosphingolipid; Reward; Signal Transduction; Sphingosine; Transforming Growth Factor beta | 2017 |
FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts.
Topics: Animals; Cell Adhesion; Cell Line; Cell Movement; Creatinine; Extracellular Matrix; Fibroblasts; Fibrosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney; Leukocytes; Male; Mice; Mice, Inbred C57BL; Rats; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Ureteral Obstruction | 2017 |
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Topics: Animals; Cell Line, Tumor; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-33; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Radiosurgery; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Tumor Burden; Tumor Microenvironment | 2017 |
Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
Topics: Adult; B-Lymphocytes; Brain-Derived Neurotrophic Factor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Inflammation; Interleukin-2; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, CXCR4; T-Lymphocytes; Transforming Growth Factor beta; Treatment Outcome | 2019 |